Drug

Pexmetinib

As of the edition of 20 October 2026, Pexmetinib is a small molecule: of no established status; acts on MAPK14 and TEK.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Status not established
Kind
Small molecule
Registered trials
1, 0 stopped early
Disease areas
Cancer; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Targets

GeneProteinUniProt
TEKAngiopoietin-1 receptorQ02763
MAPK14Mitogen-activated protein kinase 14Q16539

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase 21010
All trials1